Regenicin
Regenicin is a publicly traded, clinical-stage biotechnology company developing NovaDerm, an autologous cultured skin substitute using a proprietary collagen scaffold and patient-derived cells to treat severe burns and chronic wounds.
- Company typePublic
- Founded2010
- HeadquartersLittle Falls, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Regenicin firmographics
Firmographics- Name
- Regenicin
- Legal name
- Regenicin, Inc.
- Website
- https://regenicin.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Regenicin is a publicly traded, clinical-stage biotechnology company developing NovaDerm, an autologous cultured skin substitute using a proprietary collagen scaffold and patient-derived cells to treat severe burns and chronic wounds.
- Ownership category
- akta.pro rank
Regenicin industry classification
Industry- Product category
- Regenerative Medicine - Tissue Engineering
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)
- akta.pro secondary industries
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)
Keywords
Where Regenicin is headquartered
LocationHeadquarters
- HQ city
- Little Falls
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Regenicin business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Revenue model
- NovaDerm Product Sales: Once FDA approved, Regenicin will generate revenue from selling its autologous cultured skin substitute to hospitals and burn treatment centers. An insurance company procedural code has been approved for reimbursement, and CPT codes exist for cultured skin substitutes enabling hospitals to process claims.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Regenicin product offering
Product offeringCore offering
Regenicin develops NovaDerm, an autologous cultured skin substitute that uses a patient's own skin cells (keratinocytes and fibroblasts) expanded on a proprietary collagen biopolymer scaffold to generate living, bilayer, tissue-engineered skin for treating severe burns and chronic wounds. The product is in pre-commercial clinical development toward FDA Orphan Product approval, with planned sales directed at hospitals, burn centers, and trauma centers.
Product overview
Regenicin is a biotechnology company developing NovaDerm®, an autologous cultured skin substitute that uses the patient's own skin cells to generate living, bilayer tissue-engineered skin for severe burns and chronic wounds. The core technology involves a proprietary collagen sponge/biomedical polymer scaffold combined with expanded patient-derived keratinocytes and fibroblasts. Future pipeline includes cell banking products, diabetes treatments, adult stem cell therapies, and cosmetically elegant skin products.
Differentiator
Problem solved
Functional benefit
Brands
- NovaDerm®: An autologous cultured skin substitute for the treatment of severe burns and chronic wounds. It is the only full-thickness tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers.
Products and services
- NovaDerm® An autologous cultured skin substitute that uses a patient's own skin cells (keratinocytes and fibroblasts) expanded on a proprietary collagen biopolymer scaffold to generate living, full-thickness, bilayer tissue-engineered skin for the treatment of severe burns and chronic wounds. A small harvested skin sample can be grown to graft an area 100 times its size in 30 days. Targeted at hospitals, burn centers, and trauma centers treating catastrophic burn victims and chronic wound patients (including diabetic, pressure, and venous leg ulcers). Has received FDA Orphan-Drug Designation and is advancing toward FDA approval via the IND submission pathway.
Quantifiable outcome
- A small harvested section of the patient's own skin can be grown to graft an area 100 times its size in as little as 30 days
- +2 more outcomes
Companies that use Regenicin
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles1 record
Regenicin technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Regenicin partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Made ScientificcoreManufacturing partnership to advance NovaDerm toward FDA Orphan Product approval. Made Scientific, a U.S.-based cell therapy CDMO, provides end-to-end manufacturing services at its Princeton, New Jersey GMP facility including technology transfer, GMP clinical production, and regulatory support for IND submission and upcoming first-in-human clinical trial.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
Regenicin competitors and assessment
Company assessmentBroad incumbents
- Organogenesis Holdings: Organogenesis markets Apligraf, a leading bilayer living cell skin substitute for chronic wounds and burns, competing with NovaDerm for hospital burn/wound treatment budgets from a larger commercial platform.
- Smith+Nephew: Smith+Nephew markets Dermagraft, a bioengineered dermal substitute, providing a broad portfolio incumbent in the regenerative wound care space overlapping with NovaDerm's indications.
- ConvaTec: ConvaTec markets advanced wound care and skin substitute products through its hospital channel, competing with NovaDerm for burn and chronic wound budget share.
- Coloplast: Coloplast's wound care business sells skin substitutes and advanced wound care products for chronic wounds including diabetic ulcers, overlapping with NovaDerm's chronic wound indication.
- Integra LifeSciences: Integra LifeSciences provides regenerative skin substitutes and dermal matrices used in burns and chronic wounds, with established hospital distribution that would compete with NovaDerm upon approval.
Emerging players
- TissueTech: TissueTech develops human birth tissue-based wound and ocular therapies, addressing chronic wound healing markets that overlap with NovaDerm's chronic wound segment.
- PolarityTE: PolarityTE is a small-cap regenerative medicine company developing autologous skin and wound healing therapies, similar company stage and technological approach to Regenicin.
- MiMedx Group: MiMedx develops placental tissue allografts for wound care and surgical recovery, operating in adjacent regenerative wound healing rather than autologous full-thickness skin.
- Stratatech (Mallinckrodt subsidiary): Stratatech developed StrataGraft, a tissue-engineered skin substitute, offering a direct technical overlap to NovaDerm's tissue-engineered skin construct approach.
Direct peers
- Vericel: Vericel markets Epicel, an FDA-approved autologous cultured epidermal skin substitute for severe burns, the most directly comparable product and patient population to Regenicin's NovaDerm.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Regenicin compliance and trust
Trust signalCompliance5 records
Regenicin financial estimates
Financial estimateRevenue estimate
Valuation estimate
Regenicin leadership team
Management profileNumber of profiles
Profiles5 records
Regenicin funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Regenicin M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Regenicin
What does Regenicin do?
Regenicin develops NovaDerm, an autologous cultured skin substitute that uses a patient's own skin cells (keratinocytes and fibroblasts) expanded on a proprietary collagen biopolymer scaffold to generate living, bilayer, tissue-engineered skin for treating severe burns and chronic wounds. The product is in pre-commercial clinical development toward FDA Orphan Product approval, with planned sales directed at hospitals, burn centers, and trauma centers.
Is Regenicin a public or private company?
Regenicin is a public company. It is classified as public and is currently operating.
When was Regenicin founded?
Regenicin was founded in 2010. It employs 1 to 10 people.
Where is Regenicin based?
Regenicin is headquartered in Little Falls, United States, in the North America region.
How does Regenicin make money?
One revenue line is on record: novaDerm Product Sales.
Who are Regenicin's main competitors?
Broad incumbents on record are Organogenesis Holdings, Smith+Nephew, ConvaTec, Coloplast and Integra LifeSciences. Emerging players are TissueTech, PolarityTE, MiMedx Group and Stratatech (Mallinckrodt subsidiary). Vericel is listed as a direct peer.
Does Regenicin have an API?
No public API is recorded for Regenicin.
What industry is Regenicin in?
Regenicin's product category is Regenerative Medicine - Tissue Engineering. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials), with a secondary code of HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts). Its NAICS code is 325414 and its SIC code is 2836.